Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc. a commercial-stage biopharmaceutical company focuses on the discovery development and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria cold agglutinin disease C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis amyotrophic lateral sclerosis and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006 a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030 a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham Massachusetts.